Cand.scient. Aslaug Aamodt Muggerud from Anne-Lise Børresen-Dale's group at the Department of Genetics at the Institute for Cancer Research gave her trial lecture on the subject "Clinical utility of genetic and epigenetic markers in the management of cancer. Current status" on Friday November 13th at 10.30.
She defends her PhD thesis - entitled "Genetic and epigenetic alterations in breast tumour progression: The transition from in situ to invasive cancer" on Friday November 13th at 13.15.
Venue for both events: Auditorium U1, The Norwegian Radium Hospital at Montebello.
From major journals, first or last author from the Institute for Cancer Research
Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
Oncogene (in press)
Finding Neo (antigens, that is)
Blood, 134 (2), 108-109
Biomarker-guided therapy for colorectal cancer: strength in complexity
Nat Rev Clin Oncol (in press)